What is HC Wainwright’s Forecast for CRVS FY2025 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a research note issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.43) per share for the year, up from their prior estimate of ($0.44). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2027 earnings at ($0.32) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06).

Separately, Oppenheimer reissued an “outperform” rating and set a $15.00 price target (up from $14.00) on shares of Corvus Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Corvus Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $15.67.

Corvus Pharmaceuticals Stock Up 0.3 %

Shares of CRVS stock opened at $3.38 on Friday. Corvus Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $10.00. The company has a market capitalization of $217.19 million, a PE ratio of -3.63 and a beta of 0.91. The firm has a 50 day moving average price of $4.61 and a two-hundred day moving average price of $6.05.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. grew its position in Corvus Pharmaceuticals by 64.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after buying an additional 53,809 shares in the last quarter. State Street Corp grew its holdings in shares of Corvus Pharmaceuticals by 48.2% during the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after purchasing an additional 57,943 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter worth $265,000. XTX Topco Ltd acquired a new position in Corvus Pharmaceuticals in the third quarter valued at about $74,000. Finally, Geode Capital Management LLC raised its stake in Corvus Pharmaceuticals by 22.4% in the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after purchasing an additional 102,869 shares in the last quarter. 46.64% of the stock is owned by institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.